AbbVie's HUMIRA(R) (Adalimumab) Receives First and Only Health Canada Approval for Moderate to Severe Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a painful chronic inflammatory skin disease MONTREAL, Jan. 6, 2016 (Healthcare Sales & Marketing Network) - AbbVie, a global biopharmaceutical company, today announced that Health Canada approved HUMIRA® (adalimumab)... Biopharmaceuticals, RegulatoryAbbVie, HUMIRA, adalimumab, hidradenitis

http://salesandmarketingnetwork.com/news_release.php?ID=2040574

Source: HSMN NewsFeed - January 6, 2016 Category: Pharmaceuticals Source Type: news